Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 2a Study of HPG1860 in Subjects With NASH
Sponsor: Hepagene (Shanghai) Co., Ltd.
Summary
This is a Phase 2a, randomized, double-blind, placebo-controlled, parallel group, multiple arm, multicenter study of 3 different doses of HPG1860 versus placebo in subjects with biopsy-confirmed or phenotypic NASH.
Official title: A Randomized, Double-blind, Placebo-controlled Parallel Group Phase 2a Study to Evaluate the Efficacy and Safety of HPG1860 in Subjects With Nonalcoholic Steatohepatitis
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
89
Start Date
2021-11-22
Completion Date
2023-03-28
Last Updated
2026-05-28
Healthy Volunteers
No
Conditions
Interventions
HPG1860
The dosage form for clinical research is a dry-filled capsule for oral administration manufactured as strengths of 3 mg, 5 mg, and 8 mg.
Placebo
Capsule
Locations (1)
South Texas Research Institute (STRI)
Texas City, Texas, United States